FindTrial
Sign In

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00155376
Enrollment
100
Registered
2005-09-12
Start date
2005-09-30
Completion date
2005-09-30
Last updated
2005-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Disease

Brief summary

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

Detailed description

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

Interventions

DRUGmorphine and glucagon

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* normal volunteer * living liver donor

Exclusion criteria

* COPD * chronic liver disease * hypersensitive to glucagon * DM * insulinoma * glucagonoma * pregnancy

Design outcomes

Primary

MeasureTime frame
MRCP visibility—

Countries

Taiwan

Contacts

Primary ContactYuan-Heng Mo, MD
jamesmyh@ha.mc.ntu.edu.tw

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026